These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36694456)

  • 1. Successfully Navigating Food and Drug Administration Orphan Drug and Rare Pediatric Disease Designations for AAV9-hPCCA Gene Therapy: The National Institutes of Health Platform Vector Gene Therapy Experience.
    Lomash RM; Shchelochkov O; Chandler RJ; Venditti CP; Pariser AR; Ottinger EA;
    Hum Gene Ther; 2023 Mar; 34(5-6):217-227. PubMed ID: 36694456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases.
    Miller KL; Fermaglich LJ; Maynard J
    Orphanet J Rare Dis; 2021 Jun; 16(1):265. PubMed ID: 34107994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orphan drug designation in Europe: A booster for the research and development of drugs in rare diseases.
    Micallef J; Blin O
    Therapie; 2020 Apr; 75(2):133-139. PubMed ID: 32156423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Drug Discovery Perspective on FDA Expedited Development and Incentive Programs.
    Brown DG
    J Med Chem; 2024 Feb; 67(3):1690-1700. PubMed ID: 38233132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do investors value the FDA orphan drug designation?
    Miller KL
    Orphanet J Rare Dis; 2017 Jun; 12(1):114. PubMed ID: 28629392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
    Le TT
    Adv Exp Med Biol; 2017; 1031():183-196. PubMed ID: 29214572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
    Stockklausner C; Lampert A; Hoffmann GF; Ries M
    Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal Products.
    Palomo GM; Pose-Boirazian T; Naumann-Winter F; Costa E; Duarte DM; Kalland ME; Malikova E; Matusevicius D; Vitezic D; Larsson K; Magrelli A; Stoyanova-Beninska V; Mariz S
    Mol Ther; 2023 Dec; 31(12):3414-3423. PubMed ID: 37794679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Traits, trends and hits of orphan drug designations in cystic fibrosis.
    Costa E; Girotti S; van den Ham HA; Cipolli M; van der Ent CK; Taylor-Cousar JL; Leufkens HGM
    J Cyst Fibros; 2023 Sep; 22(5):949-957. PubMed ID: 37507282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act.
    Fermaglich LJ; Miller KL
    Orphanet J Rare Dis; 2023 Jun; 18(1):163. PubMed ID: 37353796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.
    Thorat C; Xu K; Freeman SN; Bonnel RA; Joseph F; Phillips MI; Imoisili MA
    Pediatrics; 2012 Mar; 129(3):516-21. PubMed ID: 22371464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.
    Mechler K; Mountford WK; Hoffmann GF; Ries M
    Orphanet J Rare Dis; 2015 Apr; 10():46. PubMed ID: 25896727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug development for exceptionally rare metabolic diseases: challenging but not impossible.
    Putzeist M; Mantel-Teeuwisse AK; Wied CC; Hoes AW; Leufkens HG; de Vrueh RL
    Orphanet J Rare Dis; 2013 Nov; 8():179. PubMed ID: 24237580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012.
    Pauwels K; Huys I; Casteels M; Larsson K; Voltz C; Penttila K; Morel T; Simoens S
    Orphanet J Rare Dis; 2017 Feb; 12(1):36. PubMed ID: 28209180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incentives for orphan drug research and development in the United States.
    Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL; Visaria J
    Orphanet J Rare Dis; 2008 Dec; 3():33. PubMed ID: 19087348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric Orphan Drug Indications: 2010-2018.
    Kimmel L; Conti RM; Volerman A; Chua KP
    Pediatrics; 2020 Apr; 145(4):. PubMed ID: 32127360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug development.
    Mease C; Miller KL; Fermaglich LJ; Best J; Liu G; Torjusen E
    Orphanet J Rare Dis; 2024 Feb; 19(1):86. PubMed ID: 38403586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the impact of the FDA's orphan drug designation on share prices of biotechnology companies.
    Williamson J; Spicer AJ
    Drug Discov Today; 2023 Dec; 28(12):103807. PubMed ID: 37898421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precision Medicines' Impact on Orphan Drug Designation.
    Mueller CM; Rao GR; Miller Needleman KI
    Clin Transl Sci; 2019 Nov; 12(6):633-640. PubMed ID: 31297924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.